MX2015014792A - Derivados de 2,2-difluoropropionamida de metil bardoxolona, formas polimorficas y metodos de uso de los mismos. - Google Patents

Derivados de 2,2-difluoropropionamida de metil bardoxolona, formas polimorficas y metodos de uso de los mismos.

Info

Publication number
MX2015014792A
MX2015014792A MX2015014792A MX2015014792A MX2015014792A MX 2015014792 A MX2015014792 A MX 2015014792A MX 2015014792 A MX2015014792 A MX 2015014792A MX 2015014792 A MX2015014792 A MX 2015014792A MX 2015014792 A MX2015014792 A MX 2015014792A
Authority
MX
Mexico
Prior art keywords
methods
polymorphic forms
bardoxolone methyl
difluoropropionamide
derivatives
Prior art date
Application number
MX2015014792A
Other languages
English (en)
Inventor
Ahmad Y Sheikh
Alessandra Mattei
Xiu C Wang
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of MX2015014792A publication Critical patent/MX2015014792A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere generalmente al compuesto: N-((4aS,6aR,6bS,8aR,12aS,14aR,14bS)-11-ciano-2,2,6a,6b,9,9,12a-he ptametil-10,14-dioxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,12a,14,14a, 14b-octadecahidropicen-4a-y1)-2,2-difluoropropanamida, formas polimórficas del mismo, método para preparación y uso del mismo, composiciones farmacéuticas del mismo y kits y artículos de fabricación del mismo.
MX2015014792A 2013-04-24 2014-04-24 Derivados de 2,2-difluoropropionamida de metil bardoxolona, formas polimorficas y metodos de uso de los mismos. MX2015014792A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361815502P 2013-04-24 2013-04-24
PCT/US2014/035279 WO2014176415A1 (en) 2013-04-24 2014-04-24 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2015014792A true MX2015014792A (es) 2016-03-07

Family

ID=50842351

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015014792A MX2015014792A (es) 2013-04-24 2014-04-24 Derivados de 2,2-difluoropropionamida de metil bardoxolona, formas polimorficas y metodos de uso de los mismos.

Country Status (36)

Country Link
US (4) US9856286B2 (es)
EP (2) EP3453715A1 (es)
JP (2) JP6409050B2 (es)
KR (2) KR102342915B1 (es)
CN (1) CN105324389B (es)
AR (1) AR096046A1 (es)
AU (2) AU2014257072C1 (es)
BR (1) BR112015027012B1 (es)
CA (1) CA2909066C (es)
CL (1) CL2015003135A1 (es)
CR (1) CR20150620A (es)
CY (1) CY1120570T1 (es)
DK (1) DK2989114T3 (es)
DO (1) DOP2015000263A (es)
EC (1) ECSP23088864A (es)
ES (1) ES2683626T3 (es)
HK (2) HK1221470A1 (es)
HR (1) HRP20181321T1 (es)
HU (1) HUE039899T2 (es)
IL (1) IL242183B (es)
LT (1) LT2989114T (es)
MX (1) MX2015014792A (es)
MY (1) MY182677A (es)
PE (1) PE20160006A1 (es)
PH (1) PH12015502459A1 (es)
PL (1) PL2989114T3 (es)
PT (1) PT2989114T (es)
RS (1) RS57571B1 (es)
RU (2) RU2019120236A (es)
SG (2) SG10201805231WA (es)
SI (1) SI2989114T1 (es)
TW (2) TWI649330B (es)
UA (1) UA118348C2 (es)
UY (2) UY39092A (es)
WO (1) WO2014176415A1 (es)
ZA (1) ZA201507481B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4923146B2 (ja) 2008-01-11 2012-04-25 リアタ ファーマシューティカルズ インコーポレイテッド 合成トリテルペノイドおよび疾患の治療における使用方法
ES2703274T3 (es) 2008-04-18 2019-03-07 Reata Pharmaceuticals Inc Moduladores de la inflamación antioxidantes: derivados del ácido oleanólico con modificaciones amino y otras en C-17
JP5564490B2 (ja) 2008-04-18 2014-07-30 リアタ ファーマシューティカルズ インコーポレイテッド 抗炎症性ファルマコアを含む化合物および使用法
TWI623548B (zh) 2012-04-27 2018-05-11 瑞塔醫藥有限責任公司 齊墩果酸（ｂａｒｄｏｘｏｌｏｎｅ ｍｅｔｈｙｌ）之２，２-二氟基丙醯胺衍生物、多晶型及其使用方法
US9556222B2 (en) 2012-06-15 2017-01-31 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
US9278912B2 (en) 2012-09-10 2016-03-08 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
MY180903A (en) 2012-09-10 2020-12-11 Reata Pharmaceuticals Inc C17-alkanediyl and alkenediyl derivatives of oleanolic acid and methods of use thereof
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
AR096046A1 (es) 2013-04-24 2015-12-02 Abbvie Inc Derivados de 2,2-difluoropropanamida de metil bardoxolona, formas polimórficas y métodos de uso
CN106309451A (zh) * 2016-08-14 2017-01-11 吴芊葭 一种头孢呋辛酯的药物组合物及其医药用途
CN106279344A (zh) * 2016-08-14 2017-01-04 吴芊葭 一种从防风中分离的天然化合物及其制备方法、医药应用
US10953020B2 (en) 2016-11-08 2021-03-23 Reata Pharmaceuticals, Inc. Methods of treating Alport syndrome using bardoxolone methyl or analogs thereof
CN108558985B (zh) * 2018-05-19 2019-06-07 河南省科学院高新技术研究中心 白桦脂酸衍生物及其合成方法和应用
US20210330673A1 (en) * 2018-08-15 2021-10-28 Aiviva Biopharma, Inc. Multi-kinase inhibitors of vegf and tgf beta and uses thereof
EP4364804A2 (en) 2018-08-20 2024-05-08 Janssen Pharmaceutica NV Inhibitors of keap1-nrf2 protein-protein interaction
US20200323882A1 (en) * 2019-03-15 2020-10-15 University Of Rhode Island Board Of Trustees Phlip®-mediated targeting of corticosteroids to diseased tissue
WO2020226201A1 (ko) * 2019-05-08 2020-11-12 경상대학교병원 피부 저색소증 예방 또는 치료용 약학적 조성물, 건강기능식품 및 화장료 조성물
MX2022007595A (es) * 2019-12-19 2022-07-19 Reata Pharmaceuticals Inc Triterpenoides sinteticos con sustituyentes a base de nitrogeno en c-17 y metodos de uso de los mismos.
AU2022208727A1 (en) * 2021-01-18 2023-08-03 Reata Pharmaceuticals, Inc. Synthetic ursolic acid derivatives and methods of use thereof
CN113197905B (zh) * 2021-04-23 2022-04-19 浙江大学 三萜类化合物在制备神经母细胞瘤治疗药物中的应用
CN114344308A (zh) * 2021-12-22 2022-04-15 山西医科大学第二医院 甲基巴多索隆在制备防治骨关节炎的药物中的应用
US20240124393A1 (en) * 2022-09-21 2024-04-18 Sicor - Societa Italiana Corticosteroidi S.R.L. Process and intermediates for preparation of omaveloxolone and salts thereof

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4395423A (en) 1978-10-10 1983-07-26 Sterling Drug Inc. Polycyclic cyanoketones
US5443826A (en) 1988-08-02 1995-08-22 Borody; Thomas J. Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli
US5064823A (en) 1988-08-24 1991-11-12 Research Triangle Institute Pentacyclic triterpenoid compounds as topoisomerase inhibitors or cell differentiation inducers
US5599795A (en) 1994-08-19 1997-02-04 Mccann; Michael Method for treatment of idiopathic inflammatory bowel disease (IIBD)
US6326507B1 (en) 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
US6369101B1 (en) 1999-02-26 2002-04-09 Regents Of The University Of Minnesota Therapeutic method to treat herpes virus infection
US6649654B1 (en) 1999-11-23 2003-11-18 The Regents Of The University Of California Methods for identifying and using IKK inhibitors
US6951847B2 (en) 2000-09-29 2005-10-04 Regents Of The University Of Minnesota Methods of treating fungal infections using lupeol
US6642217B2 (en) 2000-09-29 2003-11-04 Naturtek, Llc Triterpenes having human antifungal and antiyeast activity
AU2001294959A1 (en) 2000-09-29 2002-04-08 Robert M. Carlson Triterpenes having antibacterial activity
CA2430454A1 (en) 2000-11-28 2002-06-20 Board Of Regents, The University Of Texas System Cddo-compounds and combination therapies thereof
US7435755B2 (en) 2000-11-28 2008-10-14 The Trustees Of Dartmouth College CDDO-compounds and combination therapies thereof
US7176237B2 (en) 2002-01-15 2007-02-13 The Trustees Of Dartmouth College Tricyclic-bis-enone derivatives and methods of use thereof
DE60325329D1 (de) 2002-01-18 2009-01-29 Univ Minnesota Quaternäre terpensalze als biologisch aktive tenside
EP1507541A4 (en) 2002-05-13 2009-06-03 Dartmouth College HEMMER AND APPLICATION METHOD THEREFOR
WO2005042002A2 (en) 2003-10-30 2005-05-12 Entelos, Inc. Treatment of rhematoid arthritis with flip antagonists
US20060258752A1 (en) 2004-02-12 2006-11-16 Vander Jagt David L Method and compounds for cancer treatment utilizing NFkB as a direct or ultimate target for small molecule inhibitors
EP1959969A2 (en) 2005-07-01 2008-08-27 The Johns Hopkins University Compositions and methods for the treatment or prevention of disorders relating to oxidative stress
EP1996205A2 (en) 2006-03-23 2008-12-03 Advanced Life Sciences Inc. Synthetic pentacyclic triterpenoids and derivatives of betulinic acid and betulin
US20070249561A1 (en) 2006-04-25 2007-10-25 Taylor Bradley K Pharmacological method for treatment of neuropathic pain
WO2008016095A1 (fr) 2006-08-02 2008-02-07 Santen Pharmaceutical Co., Ltd. REMÈDE PRÉVENTIF OU CURATIF POUR LES KÉRATOCONJONCTIVITES CONTENANT UN ACTIVATEUR DE Nrf2 EN TANT QUE MATIÈRE ACTIVE
WO2008064133A1 (en) 2006-11-17 2008-05-29 Trustees Of Dartmouth College Synthesis and biological activities of new tricyclic-bis-enones (tbes)
US8299046B2 (en) 2006-11-17 2012-10-30 Trustees Of Dartmouth College Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth
WO2008111497A1 (ja) 2007-03-08 2008-09-18 Santen Pharmaceutical Co., Ltd. トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤
US20080254055A1 (en) 2007-04-11 2008-10-16 John Erich Oblong Compositions for Regulation of Hair Growth
WO2008136838A1 (en) 2007-05-04 2008-11-13 Trustees Of Dartmouth College Novel amide derivatives of cddo and methods of use thereof
US8088824B2 (en) 2007-08-15 2012-01-03 Reata Pharmaceuticals Inc. Forms of CDDO methyl ester
US20090048205A1 (en) 2007-08-15 2009-02-19 Colin Meyer Combination therapy with synthetic triterpenoids and gemcitabine
JP4923146B2 (ja) 2008-01-11 2012-04-25 リアタ ファーマシューティカルズ インコーポレイテッド 合成トリテルペノイドおよび疾患の治療における使用方法
WO2009146216A2 (en) 2008-04-18 2009-12-03 Reata Pharmaceuticals. Inc. Antioxidant inflammation modulators: novel derivatives of oleanolic acid
ES2703274T3 (es) 2008-04-18 2019-03-07 Reata Pharmaceuticals Inc Moduladores de la inflamación antioxidantes: derivados del ácido oleanólico con modificaciones amino y otras en C-17
EP2271658B1 (en) 2008-04-18 2016-11-09 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: c-17 homologated oleanolic acid derivatives
JP5564490B2 (ja) 2008-04-18 2014-07-30 リアタ ファーマシューティカルズ インコーポレイテッド 抗炎症性ファルマコアを含む化合物および使用法
CN102164941B (zh) 2008-04-18 2015-05-27 里亚塔医药公司 抗氧化剂炎症调节剂:具有饱和c环的齐墩果酸衍生物
US8314137B2 (en) 2008-07-22 2012-11-20 Trustess Of Dartmouth College Monocyclic cyanoenones and methods of use thereof
WO2010053817A1 (en) 2008-11-04 2010-05-14 Trustees Of Dartmouth College Betulinic acid derivatives and methods of use thereof
SI2395979T1 (sl) 2009-02-13 2017-12-29 Reata Pharmaceuticals, Inc. Peroralni farmacevtski sestavki, ki vsebujejo amorfni CDDO-Me, z zapoznelim sproščanjem
WO2010127029A1 (en) 2009-05-01 2010-11-04 Ophthotech Corporation Methods for treating or preventing ophthalmological diseases
WO2011130302A2 (en) * 2010-04-12 2011-10-20 Reata Pharmaceuticals, Inc. Method of treating obesity using antioxidant inflammation modulators
US20130288985A1 (en) 2010-07-15 2013-10-31 The Schepens Eye Research Institute Inc. Compositions and methods of treatment of corneal endothelium disorders
LT2651902T (lt) 2010-12-17 2018-01-10 Reata Pharmaceuticals, Inc. Tricikliniai pirazolil- ir pirimidinilenonai, kaip antioksidantų uždegimo moduliatoriai
ME03469B (me) 2011-03-11 2020-01-20 Reata Pharmaceuticals Inc DERIVATI C4-MONOMETIL TRITERPENOIDA l POSTUPCI ZA NJIHOVU UPOTREBU
WO2012154554A1 (en) 2011-05-06 2012-11-15 Catabasis Pharmaceuticals, Inc. Fatty acid triterpene derivatives and their uses
TWI623548B (zh) * 2012-04-27 2018-05-11 瑞塔醫藥有限責任公司 齊墩果酸（ｂａｒｄｏｘｏｌｏｎｅ ｍｅｔｈｙｌ）之２，２-二氟基丙醯胺衍生物、多晶型及其使用方法
US8921419B2 (en) 2012-05-08 2014-12-30 Trustees Of Dartmouth College Triterpenoids and compositions containing the same
WO2013169740A2 (en) 2012-05-08 2013-11-14 Trustees Of Dartmouth College Synthetic triterpenoids and methods for modulating stem/progenitor cell gene expression
US8981144B2 (en) 2012-05-08 2015-03-17 Trustees Of Dartmouth College Method for synthesizing 2-cyano-3,12-dioxoolean-1, 9(11)-dien-28-oic acid methyl ester and derivatives thereof
US9556222B2 (en) 2012-06-15 2017-01-31 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
MY180903A (en) 2012-09-10 2020-12-11 Reata Pharmaceuticals Inc C17-alkanediyl and alkenediyl derivatives of oleanolic acid and methods of use thereof
DK2892911T3 (en) 2012-09-10 2017-10-23 Reata Pharmaceuticals Inc C17 heteroaryl derivatives of oleanolic acid and methods of use thereof
MX2015003021A (es) 2012-09-10 2015-11-09 Abbvie Inc Derivados de acido glicirretinico y metodos de uso de los mismos.
US9278912B2 (en) 2012-09-10 2016-03-08 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
AR096046A1 (es) 2013-04-24 2015-12-02 Abbvie Inc Derivados de 2,2-difluoropropanamida de metil bardoxolona, formas polimórficas y métodos de uso
TWI716341B (zh) 2013-08-23 2021-01-21 美商瑞塔醫藥有限責任公司 使用齊墩果酸（ｂａｒｄｏｘｏｌｏｎｅ ｍｅｔｈｙｌ）或其類似物治療和預防內皮功能障礙之方法
US9464082B2 (en) 2014-01-24 2016-10-11 Abbvie Inc. Aryl and arylalkyl substituted pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators
CN107428698B (zh) 2015-02-12 2021-10-26 里亚塔医药公司 作为抗氧化炎症调节剂的咪唑基三环烯酮
CN108290922B (zh) 2015-09-23 2021-12-07 里亚塔医药公司 用于抑制il-17和其它用途的c4-改性的齐墩果酸衍生物
US10953020B2 (en) 2016-11-08 2021-03-23 Reata Pharmaceuticals, Inc. Methods of treating Alport syndrome using bardoxolone methyl or analogs thereof

Also Published As

Publication number Publication date
EP2989114B1 (en) 2018-05-23
UY39092A (es) 2021-03-26
TW201936625A (zh) 2019-09-16
ECSP23088864A (es) 2023-12-29
RU2015150069A3 (es) 2018-03-21
CR20150620A (es) 2016-01-12
AU2014257072A1 (en) 2015-10-29
CA2909066A1 (en) 2014-10-30
PE20160006A1 (es) 2016-02-03
SG11201508752WA (en) 2015-11-27
US11117927B2 (en) 2021-09-14
HRP20181321T1 (hr) 2018-10-19
TWI649330B (zh) 2019-02-01
CN105324389A (zh) 2016-02-10
ZA201507481B (en) 2021-05-26
US20180094020A1 (en) 2018-04-05
US20220073559A1 (en) 2022-03-10
SI2989114T1 (sl) 2018-09-28
KR20150144807A (ko) 2015-12-28
AU2014257072C1 (en) 2020-07-16
JP2016517869A (ja) 2016-06-20
IL242183B (en) 2019-10-31
RU2019120236A3 (es) 2019-12-04
EP3453715A1 (en) 2019-03-13
US20200062800A1 (en) 2020-02-27
UA118348C2 (uk) 2019-01-10
PL2989114T3 (pl) 2018-10-31
DOP2015000263A (es) 2015-12-15
AU2014257072B2 (en) 2018-10-18
KR102342915B1 (ko) 2021-12-24
KR20210018555A (ko) 2021-02-17
DK2989114T3 (en) 2018-08-20
UY35534A (es) 2014-10-31
RU2019120236A (ru) 2019-07-22
BR112015027012B1 (pt) 2023-01-10
CN105324389B (zh) 2018-02-06
HK1221470A1 (zh) 2017-06-02
CA2909066C (en) 2021-08-03
RU2693833C2 (ru) 2019-07-05
ES2683626T3 (es) 2018-09-27
JP2019023200A (ja) 2019-02-14
US20140323579A1 (en) 2014-10-30
RU2015150069A (ru) 2017-05-29
PH12015502459B1 (en) 2016-02-22
SG10201805231WA (en) 2018-08-30
LT2989114T (lt) 2018-08-10
MY182677A (en) 2021-01-29
HUE039899T2 (hu) 2019-02-28
RS57571B1 (sr) 2018-11-30
US9856286B2 (en) 2018-01-02
AU2019200341A1 (en) 2019-02-07
CL2015003135A1 (es) 2016-06-10
BR112015027012A2 (pt) 2017-07-25
EP2989114A1 (en) 2016-03-02
WO2014176415A1 (en) 2014-10-30
NZ749873A (en) 2020-09-25
AR096046A1 (es) 2015-12-02
PH12015502459A1 (en) 2016-02-22
US11873320B2 (en) 2024-01-16
TW201518314A (zh) 2015-05-16
PT2989114T (pt) 2018-10-10
JP6409050B2 (ja) 2018-10-17
CY1120570T1 (el) 2019-07-10
HK1222179A1 (zh) 2017-06-23

Similar Documents

Publication Publication Date Title
PH12015502459B1 (en) 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof
MY172750A (en) 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof
SV2017005487A (es) Derivados de 4h-pirrol[3,2-c]piridin-4-ona
MX348862B (es) Derivados c4-monometil triterpenoides y sus metodos de uso.
WO2016013030A3 (en) Hydroxysteroid compounds, their intermediates, process of preparation, composition and uses thereof
BR112016001876A2 (pt) composto de benzoxaborol tricíclico, método de preparação e uso do mesmo
AU2014324961A8 (en) Highly potent glucocorticoids
WO2016092561A3 (en) Novel polymorphs of ivacaftor, process for its preparation and pharmaceutical composition thereof
WO2015052568A3 (en) Solid forms of curcumin and derivatives thereof
BR112015030589A8 (pt) formas polimórficas de fosfato de icotinibe, composição farmacêutica compreendendo as referidas formas e usos das mesmas
AR124675A2 (es) Derivados de 2,2-difluoropropanamida y metil bardoxolona, formas polimórficas y métodos de uso
IN2013CH05591A (es)
LV15016A (lv) N-karbamoilmetil-4(R)-fenil-2-pirolidinona polimorfās formas

Legal Events

Date Code Title Description
FG Grant or registration